目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T14141 | Others Methionine Adenosyltransferase (MAT) | ||
AGI-24512 是一种甲硫氨酸腺苷转移酶 2A 抑制剂,在体外能够阻断 MTAP 缺失的癌细胞的生长,可用于研究癌症。 | |||
T15578 | Topoisomerase | ||
Indotecan (LMP-400) 是一种有效的拓扑异构酶 1 抑制剂,对 P388、HCT116和MCF-7 细胞系的IC50值分别为 300、1200和560 nM。 | |||
T64391 | Others | ||
Antiproliferative agent-15是一种具有抗癌活性的试剂。Antiproliferative agent-15对人结肠癌(HCT116和HCT15)和脑癌(LN-229和GBM-10)具有抗增殖活性。 | |||
T21854 | Proteasome | ||
Proteasome inhibitor IX (PS-IX) 是 Chalcone 的一种衍生物,对20S 蛋白酶体的胰凝乳蛋白酶样活性有抑制作用,IC50约为 1 μM。它抑制 HCT116 p53+/+细胞生长,IC50为 1.49 μM,显示出有效的抗癌活性。 | |||
T61722 | Apoptosis | ||
ZDLD20 是一种具有口服活性和选择性的CDK4抑制剂,是一种 β-咔啉类化合物,具有抗 HCT116 和抗癌活性,抑制集落形成、抑制侵袭和迁移、诱导细胞凋亡和阻止细胞周期的 G1 期。 | |||
T36970 | DUB | ||
STD1T 是一种具有选择性和有效性的脱泛素酶 USP2a 抑制剂,具有潜在的抗癌活性,可降低 HCT116 结肠和 MCF-7 乳腺癌细胞中的细胞周期蛋白 D1 蛋白水平。 | |||
T2S0357 | Others Carbonic Anhydrase | ||
6-Hydroxycoumarin (6-hydroxychromen-2-one) 是一种香豆素。其中香豆素具有抗炎,支气管扩张,解热,血管扩张,抗氧化,抗菌,抗真菌,抑菌和抗肿瘤作用。 | |||
T24131 | Histone Demethylase Antiviral | ||
HDAC3-IN-T247 (HDAC3 inhibitor T247) 是一种具有选择性和有效性的组蛋白去乙酰化酶 3(HDAC3) 抑制剂,具有抗癌和抗病毒活性。HDAC3-IN-T247 以剂量依赖的方式诱导人结肠癌 HCT116 细胞中 NF-κB 乙酰化。HDAC3-IN-T247 抑制癌细胞增殖。 | |||
T78156 | Apoptosis | ||
MC4033是一种选择性的,可逆的KAT8赖氨酸乙酰转移酶抑制剂,IC50为12.1μM,具有抗癌活性,并能诱导凋亡(apoptosisautophagy)。 | |||
T6843 | Apoptosis MEK | ||
GDC-0623 (RG 7421) 是一种 ATP 竞争性的MEK1抑制剂,Ki 值为 0.13 nM。它对 A375 细胞中 BRAFV600E 的 EC50值为 7 nM,而对 HCT116 细胞中 KRAS (G13D)的 EC50值为 42 nM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04023 | BCCIP Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
BCCIP was originally identified as a BRCA2 and CDKN1A interacting protein that has been implicated in maintenance of genomic stability, cell cycle regulation, and microtubule dynamics. The secondary genetic alternations may overcome the progression suppression imposed by BCCIP deficiency through a synthetic viability mechanism. Knockdown of YY1 inhibited the binding of BCCIP itself at BCCIP promoter region proximal to TSS, demonstrating that transcriptional regulation of the YY1 on BCCIP can be modulated by BCCIP itself in a YY1-dependent fashion. BCCIP (BRCA2 and CDKN1A interacting protein) plays a critical role in maintaining the critical functions of p53 in tumor suppression and response to therapy. Celecoxib affects the functions of p53 and inhibits the recovery from the irradiation-induced injury by up-regulating the expression of BCCIP, and subsequently regulates the expressions of genes such as p21 and Cyclin B1 to enhance the radiosensitivity of HCT116 cells in a COX-2 independent manner.
|
|||||
TMPY-00578 | BCCIP Protein, Human, Recombinant | Human | Baculovirus-Insect Cells | ||
BCCIP was originally identified as a BRCA2 and CDKN1A interacting protein that has been implicated in maintenance of genomic stability, cell cycle regulation, and microtubule dynamics. The secondary genetic alternations may overcome the progression suppression imposed by BCCIP deficiency through a synthetic viability mechanism. Knockdown of YY1 inhibited the binding of BCCIP itself at BCCIP promoter region proximal to TSS, demonstrating that transcriptional regulation of the YY1 on BCCIP can be modulated by BCCIP itself in a YY1-dependent fashion. BCCIP (BRCA2 and CDKN1A interacting protein) plays a critical role in maintaining the critical functions of p53 in tumor suppression and response to therapy. Celecoxib affects the functions of p53 and inhibits the recovery from the irradiation-induced injury by up-regulating the expression of BCCIP, and subsequently regulates the expressions of genes such as p21 and Cyclin B1 to enhance the radiosensitivity of HCT116 cells in a COX-2 independent manner.
|